Directorate Change

RNS Number : 3916H

Mediclinic International plc

15 November 2018

 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

15 November 2018

DIRECTORATE CHANGE

The Company announces that on 14 November 2018, Mr Desmond Smith, the Company's Senior Independent Director, informed the Board of his intention to retire as a director of the Company at the conclusion of the Company's Annual General Meeting ("AGM") scheduled for 24 July 2019 and not seek re-election at the AGM. Mr Smith will also step down from all Board committees at that time.   

Mr Alan Grieve will succeed Mr Smith as Senior Independent Director of the Company and as Chairman of the Audit and Risk Committee, to be effective from the date of Mr Smith's resignation in 2019. 

Further changes to the constitution of the Company's committees will be made and announced in due course.

Mediclinic's chairman, Dr Edwin Hertzog commented:

"On behalf of my colleagues on the Board, I would like to thank Desmond for his commitment and valued contributions to the Board and the Group over many years."

This announcement is made in accordance with the requirement of LR 9.6.11.

About Mediclinic International plc

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

Mediclinic comprises 76 hospitals and 30 clinics. Hirslanden operates 18 private hospitals and 4 clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operates 48 hospitals and 4 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 7 hospitals and 22 clinics with more than 900 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

 

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

[phone]

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[e-mail]

[phone]

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

[phone]

Sherryn Schooling - South Africa

[phone]

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

 

END

 

 

BOAGGGMCGUPRGQC